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A Polymorphism Associated with Depressive Disorders
Differentially Regulates Brain Derived Neurotrophic
Factor Promoter IV Activity
Benjamin Hing, Scott Davidson, Marrisa Lear, Gerome Breen, John Quinn, Peter McGuffin, and
Alasdair MacKenzie
Background: Changes in brain derived neurotrophic factor (BDNF) expression have been associated with mood disorders and cognitive
dysfunction. Transgenic models that overexpress or underexpress BDNF demonstrate similar deficits in cognition and mood. We explored
the hypothesis that BDNF expression is controlled by balancing the activity of BDNF promoter IV (BP4) with a negative regulatory region
containing a polymorphism associated with cognitive dysfunction and mood disorders.
Methods: We used comparative genomics, transgenic mouse production, and magnetofection of primary neurons with luciferase report-
ers and signal transduction agonist treatments to identify novel polymorphic cis-regulatory regions that control BP4 activity.
Results: We show that BP4 is active in the hippocampus, the cortex, and the amygdala and responds strongly to stimuli such as potassium
chloride, lithium chloride, and protein kinase C agonists. We also identified a highly conserved sequence 21 kilobase 5’ of BP4 that we called
BE5.2, which contains rs12273363, a polymorphism associated with decreased BDNF expression, mood disorders, and cognitive decline.
BE5.2 modulated the ability of BP4 to respond to different stimuli. Intriguingly, the rarer disease associated allele, BE5.2(C), acted as a
significantly stronger repressor of BP4 activity than the more common BE5.2(T) allele.
Conclusions: This study shows that the C allele of rs12273363, which is associated with mood disorder, modulates BP4 activity in an
allele-specific manner following cell depolarization or the combined activity of protein kinase A and protein kinase C pathways. The
relevance of these findings to the role of BDNF misexpression in mood disorders and cognitive decline is discussed.
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Major depressive disorder (MDD) and bipolar disorder (BD)are psychiatric diseases that not only increase morbiditybut also impair cognition. A gene strongly implicated in
these disorders is the brain derived neurotrophic factor (BDNF).
Brain derived neurotrophic factor is a neurotrophin that mediates
neuroplastic processes, such as neurogenesis (1), synaptic plasticity
(2), dendritic arborization (3), and development and maturation of
-aminobutyric acid (GABA)ergic neurons (4,5). As such, alterations
to BDNF expression level could impair these cellular processes af-
fecting brain structures and their function.
Indeed, reduced BDNF expression has been observed in the
hippocampus and prefrontal cortex of MDD and BD patients (6–8),
coinciding with reduced volume of these structures (9–13), im-
paired spatial memory (14,15), and executive function (16,17), re-
spectively. Interestingly, overexpression and underexpression of
BDNF in different parts of the brain of mice impaired their learning
and memory and precipitated depression-like behavior (18–20).
Together, these studies highlight that fine regulation of BDNF ex-
pression level is required for mental health. This can be mediated by
BDNF promoter activity.
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0006-3223
doi:10.1016/j.biopsych.2011.11.030To date, BDNF promoter IV (BP4) has been the most well-studied
romoter of the nine alternative BDNF promoters and has also been
hown to be important for mental health (21–25). For example, BP4
utant mice have depression-like symptoms and impaired mem-
ry (26,27). As promoter regions are often insufficient to maintain
orrect messenger RNA (mRNA) expression levels in appropriate
ells and in response to appropriate cues, cis-regulatory elements
CREs) are frequently required to modulate promoter activity so
hat transcriptional levels appropriate to health are maintained
28–31). Genetic variations, such as single nucleotide polymor-
hisms (SNP), in CREs can disrupt transcription factor binding sites,
esulting in misregulation of gene expression causing physical
hanges and even disease susceptibility (32–35).
Recently, a study demonstrated that the minor allele of an SNP
rs12273363) that lies in an intergenic region upstream of the BDNF
ene was associated with MDD susceptibility in patients with a
istory of childhood adversity (36). Considering the requirement for
nely balanced levels of BDNF expression described in the studies
bove, we explored the hypothesis that this intergenic region
here the SNP resides may be a CRE that modulates the activity of
P4 in response to specific stimuli. In addition, the SNP rs12273363
ight alter the activity of this, as yet, unidentified CRE required to
odulate appropriate levels of BP4 activity essential for health.
ethods and Materials
ioinformatic Analysis
To identify evolutionary conserved regions (ECRs), comparative
enomics was performed using the ECR genome browser (http://
crbrowser.dcode.org/) (37) and the University of California Santa
ruz genome browser (http://genome.ucsc.edu/). Allele frequency
f SNPs was determined using the National Center for Biotechnol-
gy Information Single Nucleotide Polymorphism Database (http://
ww.ncbi.nlm.nih.gov/SNP/).
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B. Hing et al. BIOL PSYCHIATRY 2012;71:618–626 619Plasmid Construction
Human BP4 and BE5.2 (T) were amplified using high-fidelity poly-
merase chain reaction (Expand High Fidelity System; Roche Diagnos-
ticsLimited,WestSussex,UnitedKingdom)fromhumanDNA(Cambio,
Cambridge, United Kingdom). Primers used were BP4 forward primer
5’-CTGCTCCGGGAAAGACTTC-3’ and reverse primer 5’-ACCCTCGAAT-
CACCTACCC-3’; BE5.2 forward primer 5’-GGAAATCTCGGGAAATA-
GGC-3’andreverseprimer5’-GACCCATCTCAGGTCTCCAG-3’.Products
were ligated into pGEM-T Easy Cloning Vector (Promega, Southamp-
ton, United Kingdom). All amplified DNA samples were sequenced
(Source Bioscience, Nottingham, United Kingdom) to ensure correct
sequence and orientation as genomic sequence, as stated in the Uni-
versity of California Santa Cruz browser.
BP4. Brain derived neurotrophic factor promoter IV was re-
tricted from pGEM-T Easy using NcoI and Eco53KI and cloned into
GL4.23 that had been digestedwith NcoI and EcoRV (Promega) to
eplace the minimal promoter.
BP4 BE5.2(T). Brain derived neurotrophic factor promoter IV
as restricted from pGEM T Easy using NcoI and SpeI, while BE5.2
as restricted using SpeI and ZraI. They were subsequently ligated
nto pGL4.23, which had been digested with NcoI and EcoRV to
emove the minimal promoter.
BP4 BE5.2(C). The major allele T was substituted with the
inor allele C by site-directed mutagenesis using QuickChange II
ite-directed mutagenesis kit (Agilent Technologies, Cheadle,
nited Kingdom). Primers used were forward primer 5’-ACAGC-
ATGCTGCAGAAGACGGTGGATAGCTC-3’ and reverse primer 5’-
AGCTATCCACCGTCTTCTGCAGCATCGCTGT-3’.
BP4. Tocontrol for cell-specificor treatmenteffectsonthepGL4
lasmid backbone, we produced a plasmid identical to the pGL4.23
P4plasmidbut that lackedBP4. Theminimal promoterwas removed
rom pGL4.23 using NcoI and Bgl II and subsequently blunt-ended
singDNApolymerase I large Klenow fragment before ligation.
BP4 LacZ. Brain derived neurotrophic factor promoter IV was
emoved from pGEM T Easy using NcoI and EcoICRI (Promega) and
igated into the SphI (made blunt end using Klenow fragment) and
coI site of the p1230 plasmid (a kind gift from Robert Krumlauf,
towers Institute, KansasCity,Missouri) that encodes aLacZmarker.
rimary Cell Culture
Hippocampal, cortex, and amygdala tissues, as previously de-
ned (38), were dissected from postnatal day 0 to day 3 wild-type
prague Dawley rat pups that were humanely sacrificed according
o United Kingdom Home Office guidelines. Tissues were treated
ith .05% trypsin ethylenediaminetetraacetic acid (Invitrogen,
aisley, Scotland, United Kingdom) for 15 minutes at 37oC. Trypsin
ethylenediaminetetraacetic acid was replaced with soybean tryp-
sin inhibitor (Sigma, Irvine, Scotland, United Kingdom) for 5 min-
utes at room temperature to stop reaction. This was then replaced
t
Cith unsupplemented Neurobasal A (Invitrogen) followed by me-
hanical dissociation. Cellswere then resuspended in culturemedia
Neurobasal A, B27 [Invitrogen], 1X GlutaMAX [Invitrogen], and
en/strep [100 U/mL] [Invitrogen]) and plated out at a density of
igure 2. Diagrams representing luciferase constructs used for the investi-
ation and comparative genomic analysis to identify BE5.2 and allelic fre-
uency of rs12273363 in different human populations. (A) Diagrammatic
epresentation of the different luciferase constructs used to investigate the
ffects of different allelesof BE5.2 andonhumanbrainderivedneurotrophic
actor promoter 4 (BP4) activity (not to scale). (B) Stacked pairwise align-
ent from the evolutionary conserved region genome browser between
enomic sequences of different animal species (in descending order;
hicken, possum, mouse, dog, and rhesus macaque) against the human
enomic sequence. Brain derived neurotrophic factor promoter 4 and BE5.2
re indicated by a black box and the direction of transcription from BP4 is
ndicated by a bent black arrow. The single nucleotide polymorphism
s12273363 is found in BE5.2. Yellow, pink, green, blue, and red peaks
ighlight areas of conservation in untranslated regions, introns, repetitive
egions, coding regions, and intergenic DNA, respectively (from evolution-
ry conserved region genome browser). The position of rs12273363 is indi-
ated below BE5.2. (C) Allelic frequency of rs12273363 in different human
opulations from the National Center for Biotechnology Information single
ucleotide polymorphism database. BDNF, brain derived neurotrophic fac-
Figure 1. Brain derived neurotrophic factor promoter 4
can support LacZ expression in cortex, hippocampus, and
amygdala. (A–C) Photomicrographs of 60-m sections of
brain derived neurotrophic factor promoter 4-LacZ neo-
natal (postnatal days 3–7) transgenic mouse brains fol-
lowing staining by X-Gal showing LacZ expression (blue
cells) in the amygdala (A), hippocampus (B), and prefron-
tal cortex (C). Scale bars represent 500 m (A), 1000 m
(B), and 880 m (C), respectively. BLA, basolateral
amygdala; CA, cornu ammonis; CeA, central amygdala;
Hippo, hippocampus; PC, piriform cortex; PFC, prefrontal
cortex.or; CEU, Central Europeans; Chrom., chromosome; Cnt., count; HCB, Hans
hinese in Bejing; JPT, Japanese in Tokyo; YRI, Yoruba in Ibadan.
www.sobp.org/journal
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w80,000 viable cells/cm2 on Poly-L-Lysine (20 g/mL) (Sigma) pre-
treated plates following cell counting for viable cells using TC10
automated cell counter (Biorad, Hemel Hempstead, United King-
dom) with trypan blue. Cells were incubated at 37oC, 5% carbon
dioxide for 7 days before transfection.
Transfections and Treatments
All DNA constructs were quantified on a nanodrop machine
(NanoDrop Technologies, Thermo Scientific, Southend-on-Sea,
United Kingdom). Quantities of plasmid used for each transfection
were adjusted to the size of each plasmid to ensure molar equiva-
lence between experiments. Firefly luciferase plasmids were co-
transfected with Renilla luciferase plasmid, pGL4.70 (Promega), to
normalize signals between transfections using magnetic particles
(Neuromag; Oz Bioscience, United Kingdom) as described in man-
ufacturer’s instructions. Primary neuronal cultures were incubated
for 24 hours before agonist or vehicle treatment. Stock potassium
chloride (KCl) and lithium chloride (LiCl) treatments were prepared
in culture media, whereas phorbol-12-myristate-13-acetate (PMA)
was prepared in dimethyl sulfoxide or ethanol. Forskolin (Sigma)
was prepared in dimethyl sulfoxide (Sigma). All treatments were
diluted in culture media to the following concentrations for use
unless otherwise stated: 60 mmol/L KCl, 1 mmol/L LiCl, 150 nmol/L
PMA, 25 mol/L forskolin. Cultures treated with KCl, PMA, and
forskolin were incubated for 24 hours before harvest for dual lu-
ciferase assay. To maintain consistency with previous studies, cul-
tures treated with 1 mmol/L LiCl were incubated for 72 hours as
previously described (39) before harvest for dual luciferase assay.
Dual Luciferase Assay
Cells were harvested and dual luciferase assays were performed
as described inmanufacturer’s instructions using GloMax 96Micro-
plate Luminometer with dual injectors (Promega).
Transgenic Mouse Production
Transgenic mice were generated as previously described (40).
Analysis of LacZ Gene Expression in Transgenic Lines
Neonate (2–7 days old) F1 transgenic mouse brains were fixed
and stained as previously described (41). X-Gal (Sigma) stained
tissues were then prepared for vibratome sectioning as previously
described (42). i
ww.sobp.org/journalata Analysis
All experiments were performed at least three independent
imes in triplicate (i.e.,n 3). Statistical significance of data setswas
nalyzed using either two-way analysis of variance with post hoc
olm-Sidak test using SigmaPlot Build 11.0.0.75 (Systat Software
nc., Hounslow,UnitedKingdom)or two-tailedunpairedparametric
tudent t test using GraphPad PRISM version 5.02 (GraphPad Soft-
are, La Jolla, California), where appropriate.
esults
P4 is Active in the Amygdala, Hippocampus, and Cortex of
ransgenic Mice
Although agreat deal has beendiscovered about the role of BP4
n thebrain andbehavior (21,26,27), little is knownabout the tissue-
pecific activity of BP4 in vivo. To address this deficit, three trans-
enic mouse lines were created that expressed the LacZ gene un-
er the control of human BP4. Coronal brain sections derived from
hese transgenic lines showed consistent X-Gal staining present in
tructures in the hippocampus, prefrontal cortex, and amygdala
Figure 1A–C). These expression patterns produced by the BP4-
acZ transgene closely resembled endogenous mouse BDNF exon
X mRNA distribution documented in the Allen Institute for Brain
cience Brain Atlas (http://www.brain-map.org/).
ctivity of BP4 in Untreated Primary Hippocampal, Cortical,
nd Amygdala Cultures
To investigate BP4 activity in primary cell culture, BP4 was
loned into a luciferase plasmid (Figure 2A) and transfected into
rimary neuronal cultures. BP4 induced significantly higher lu-
iferase activity than the control plasmid, BP4, in primary hip-
ocampal cultures (Figure 3A), cortical cultures (Figure 3B), and
mygdala cultures (Figure 3C).
Cl Depolarization Upregulates Both Endogenous BDNF Gene
xpression and BP4 Activity in Primary Hippocampal, Cortical,
nd Amygdala Cultures
In previous studies, BP4 activitywas observed tobeupregulated
ollowing neuronal depolarization using KCl (23,24,43). We there-
ore investigated whether endogenous BDNF gene expression or
P4 responded to KCl depolarization in our primary cell paradigms.
onsistentwith these previous studies,weobserved that KCl signif-
Figure 3. Brain derived neurotrophic factor promoter 4
(BP4) and brain derived neurotrophic factor activity in
primary neuronal cultures following potassium chloride
(KCl) depolarization. Primary hippocampal (A, D) cortical
(B, E), and amygdala (C, F) cultures were co-transfected
with BP4 and renilla plasmid. Cells were either untreated
(A–C) or treated (D–F) with 60 mmol/L KCl for 24 hours
before harvesting for analysis by dual luciferase assay.
Relative light units were calculated by normalizing lu-
ciferase signal to renilla signal. n 3, **p .01.cantly increased endogenous rat BDNF exon IV and exon XI (data
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B. Hing et al. BIOL PSYCHIATRY 2012;71:618–626 621not shown). This coincided with a significant increase in BP4 lu-
ciferase activity in hippocampal (Figure 3D), cortical (Figure 3E), and
mygdala cultures (Figure 3F) compared with untreated cultures.
hese results demonstrate parity of our current primary cell model
ystemwith previous studies (23,24,43). TheBP4 did not respond to
Cl depolarization in any of the cell types studied (data not shown).
omparative Genomics Identified a Novel Polymorphic
utative Cis-regulatory Element Upstream of Human BP4
In concert with previous studies, we have shown that BP4 is
ctive in specific parts of the brain and responds to KCl depolariza-
ion (22,44–46). As no SNPs to date havebeen identified in BP4 that
ffects its activity or associateswithdisease,wehypothesized that a
econd regulatory element in the form of a CRE harbors disease-
elated genetic mutation in and around the BDNF locus. We have
reviously shown that comparativegenomics is a powerfulmethod
o identify novel CREs that may lie some distance from the pro-
oter regions they affect (40,42,47–49). Using the ECR genome
rowser,we identifiedahighly conservedECR that lay21kilobase
airs upstream of BP4 in an intergenic region (Figure 2B). This ECR
BE5.2)was highly conserved (75.9% similarity over 793basepair) in
lacental mammals representing 92million years of divergent evo-
ution (50) and coincided with the location of an SNP, rs12273363,
hat had previously been associated with a number of conditions
ncluding MDD and BD (36,51) and resulted in a T-C change within
E5.2. Since BP4 is active in the hippocampus, cortex, and
mygdala, the effects of the two different alleles of BE5.2 on BP4
ctivity were investigated in primary neuronal cultures derived
rom these brain structures. From the Single Nucleotide Polymor-
hismDatabase (http://www.ncbi.nlm.nih.gov/SNP/), the allele T is
he major allele, while the allele C is the minor allele in all investi-
ated human populations (Figure 2C). As such, BE5.2 containing
he major allele T or minor allele C will be termed BE5.2(T) and
E5.2(C), respectively, for the rest of the investigation. CE5.2(T) Reduces BP4 Activity in Untreated Primary
ippocampal, Cortical, and Amygdala Cultures but Permits
pregulation of BP4 Activity by KCl
To investigate the effect of BE5.2(T) on BP4, BE5.2(T) was cloned
nto a luciferase plasmid upstream of BP4 (Figure 3A) and trans-
ected into three different primary neuronal cultures. BP4-BE5.2(T)
educed luciferase activity compared with BP4 in all untreated pri-
ary cell cultures, suggesting that BE5.2 acts to suppress BP4 activ-
ty (Figure 4A–C).
Although the response of BP4 was reduced by BE5.2(T) (Figure
G–I), BE5.2(T) permitted activation of BP4 by KCl treatment in all
rimary cell cultures used (Figure 4D–F).
E5.2 Demonstrates Significant Allele-Specific Differences in
ts Ability to Reduce BP4 Response to KCl Depolarization in
rimary Hippocampal and Amygdala Cultures
To detect functional differences between the two alleles of
E5.2, primary neuronal cultures were transfected with BP4-
E5.2(T) and BP4-BE5.2(C). In all untreated primary neuronal cul-
ures, no significant difference in luciferase activity was observed
etween BP4-BE5.2(T) and BP4-BE5.2(C) (Figure 5A–C). Both BP4-
E5.2(T) (Figure 4D–F) and BP4-BE5.2(C) responded to KCl in hip-
ocampal (Figure 5D), cortical (Figure 5E), andamygdala (Figure 5F)
ultures. However, BE5.2(C) did not permit BP4 to respond as
trongly as BE5.2(T) to KCl depolarization in primary hippocampal
Figure 5G) and cortical cultures (Figure 5H). By contrast, in
mygdala cultures, BP4-BE5.2(C) had significantly increased re-
ponse to KCl compared with BP4-BE5.2(T) (Figure 5I).
E5.2 Abolished BP4 Response to LiCl in Primary Cortical
ultures
Recently, the established antidepressant and Wnt agonist LiCl
as shown to increase rat BP4 activity in primary cortical cultures
39). We, therefore, investigated the effect of the different alleles of
E5.2 on BP4 response toWnt signaling in primary cortical cultures.
Figure 4. Brain derived neurotrophic factor promoter 4
(BP4) and BP4-BE5.2(T) response to potassium chloride
(KCl) depolarization in primary neuronal cultures. Primary
hippocampal (A, D, E), cortical (B, E, H), and amygdala (C,
F, I) cultureswere co-transfectedwithBP4or BP4-BE5.2(T)
and renilla plasmid. Cells were either untreated (A–C) or
treated (D–I) with 60 mmol/L KCl for 24 hours before
harvesting for analysis by dual luciferase assay. Relative
light units were calculated by normalizing luciferase sig-
nal to renilla signal.n3,**p .01, *p .05,notsignificant;
#two-way analysis of variance p .05 but t test p .01.onsistent with previous studies, LiCl significantly increased BP4
www.sobp.org/journal
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wactivity in primary cortical cultures (Figure 6A). However, in the
presence of either BE5.2(C) or BE5.2(T), BP4 activation by LiCl was
abolished (Figure 6B). No significant allele-specific differenceswere
observed.
BE5.2 Prevents Increase of BP4 Activity by PMA and Forskolin
It has been previously shown that KCl activates the protein
kinase C (PKC) (52,53) andprotein kinase A (PKA) pathways (54–57),
which have been shown to increase BDNF exon IV expression
(58,59).We, therefore, investigated if either of these signaling path-
ways acted on BP4 andwhether BE5.2modulated the BP4 response
in any way. First of all, cortical cultures were treated with PMA, an
agonist of the PKC pathway (60). Phorbol-12-myristate-13-acetate
significantly increased BP4 activity (Figure 6C). However, both
BE5.2(T) andBE5.2(C) abolished theability of BP4 to respond toPMA
(Figure 6D).Moreover, treatmentwith forskolin didnot significantly
upregulate activity of BP4 and neither BE5.2(T) nor BE5.2(C)
changed this response significantly (Figure 6E,F).
BE5.2(T) and BE5.2(C) Display Significant Allele-Specific
Differences in Their Ability to Suppress BP4 Activity Following
Combined Stimulation by PKC and PKA Pathways
Because KCl depolarization is known to alter BDNF gene expres-
sion through activation of both PKA and PKC pathways, we investi-
gated the hypothesis that activation of BP4 by KCl required a com-
bination of both these pathways. When transfected cortical
cultureswere treatedwith both PMAand forskolin, BP4 activitywas
significantly increased (Figure 7A). However, in contrast to our pre-
vious observations, whereby BE5.2 abolished activation of BP4 by
PMA, BE5.2permittedPMAactivationof BP4 in thepresenceofboth
forskolin and PMA (Figure 7A,B). This suggests that PKC and PKA
pathways work synergistically through BE5.2 to permit BP4 activa-
tion by PMA. Significantly, we were also able to observe that
BE5.2(C) was less permissive of BP4 activation by PMA and forskolin p
ww.sobp.org/journalhan BE5.2(T) (Figure 7B,C). These observations are consistent with
ur previous observations of differential allelic response following
Cl depolarization (Figure 5H).
iscussion
In the current study, we have shown that human BP4 is active in
ells of the prefrontal cortex, cortex, hippocampus, and amygdala
n a pattern that mirrors the expression pattern of endogenous
ouse BDNF mRNA (22,44–46). These results confirm previous
tudies using transgenic mice carrying a bacterial artificial chromo-
ome containing the human BDNF locus that also showed BDNF
xpression in these regions (45). However, these bacterial artificial
hromosome-based studies could not attribute the expression pat-
erns produced directly to BP4. In a separate study using human
issues, reverse transcription polymerase chain reaction also
howed BDNF exon IV expression in prefrontal cortex, cortex, hip-
ocampus, and amygdala (21). This study was, however, unable to
emonstrate that BP4 itself was sufficient to direct BDNF exon IV
xpression in these brain structures independent of CREs, since
REs are known to be able to direct the spatial activity of promoters
61,62). To circumvent this problem, we expressed LacZ under the
egulation of BP4 in mice and demonstrated, for the first time, that
uman BP4 is active in brain structures that express BDNF mRNA
nd are known to be altered in MDD and BD (10–13,63,64). In
ddition, the current study demonstrates that BP4 is a highly active
ositive regulatory element whose activity is further increased by a
umber of different signal transduction pathways. However, the
ossibility that BP4 is solely responsible for controlling BDNF ex-
ression is inconsistent with previous studies demonstrating that
verexpression or underexpression of BDNF affects behavior and
ognition in a similarway (18,20). Considering the requirement for a
ne balancing of BDNF expression levels in health and the strong
Figure5.Comparisonof BE5.2(T) andBE5.2(C) interaction
with brain derived neurotrophic factor promoter 4 (BP4)
in potassium chloride (KCl) depolarized hippocampal,
cortical, and amygdala cultures. Primary hippocampal (A,
D), cortical (B, E), and amygdala (C, F) cultures were co-
transfected with either BP4-BE5.2(T) or BP4-BE5.2(C) with
renilla plasmid. Cells were untreated (A–C) or treated
(D–I) with 60 mmol/L KCl for 24 hours before harvest for
dual luciferase assay. Relative light units were calculated
by normalizing luciferase signal to renilla signal. Fold in-
duction was calculated by dividing relative light units of
treated culture by relative light units of vehicle-treated
cultures. n 3, **p .01, *p .05. n.s., not significant.ositive role of BP4 in activating gene expression (analogous to an
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B. Hing et al. BIOL PSYCHIATRY 2012;71:618–626 623accelerator), we explored the hypothesis that some type of balanc-
ing negative regulator may be required to allow appropriate con-
trol of BDNF levels (i.e., a brake).
Many studies have reported examples of negative regulation
(61,65). Indeed, SNPs in silencer elements have been observed to
contribute to disease and anxiety traits (66–68). Silencer elements
have been known to not only reduce promoter activity but to
also abolish promoter response to stimuli (69–71). In line with
this, our study identified a highly conserved CRE called BE5.2,
which contained a polymorphism associated with mood disor-
ders that reduced BP4 activity in all our primary neuronal cultures
Figure 7. Combined treatment of phorbol-12-myristate-13-acetate (PMA) a
promoter 4 (BP4) BE5.2 (T) andBP4BE5.2 (C) in cortical cultures. Primary corti
E5.2(C). Cells were treated with 150 nmol/L PMA and 25mol/L forskolin o
ual luciferase assay. Relative light units were calculated by normalizing luc
ight units of treated culture by relative light units of vehicle-treated cultures. n
p .05.nd abolished BP4 response to PKC activation by PMA treatment.
ntriguingly, BE5.2 permitted BP4 response to KCl depolarization,
lthough at lower levels, which is a novel and interesting property
f silencer elements never observed before. Although BE5.2
lockedBP4activationby thePKCpathway,weeventually deduced
hat BE5.2 permitted activation of BP4 by PKC but only if the PKA
athway was also activated. Based on these observations, we
ropose the hypothesis that BE5.2 does not act as an indiscrim-
nate silencer but rather filters signaling information appropriate
or normal BP4 response to neuron activation. Our data suggest
hat this information filtering system selectively favors BDNF
Figure 6. Interaction of BE5.2 (C and T) with brain derived
neurotrophic factor promoter 4 (BP4) in response to lith-
ium chloride (LiCl), phorbol-12-myristate-13-acetate
(PMA), and forskolin in primary cortical cultures. Primary
cortical cultures were co-transfected with either BP4 (A,
C, D) or BP4-BE5.2(T), BP4-BE5.2(C), orBP4 (B, D, E)with
renilla plasmid. Cells were treated with 1 mmol/L LiCl for
72 hours (A, B), 150 nmol/L PMA for 24 hours (C, D), or
forskolin for 24 hours (E, F) before harvest for dual lu-
ciferase assay. Relative light units were calculated by nor-
malizing luciferase signal to renilla signal. n 3, **p .01.
DMSO, dimethyl sulfoxide; n.s., not significant.
skolin increased luciferase expression by brain derived neurotrophic factor
ltureswere co-transfectedwith either (A)BP4or (B, C)BP4BE5.2(T) andBP4
ethyl sulfoxide (DMSO) as vehicle treatment for 24 hours before harvest for
e signal to renilla signal. Fold induction was calculated by dividing relative
#nd for
cal cu
r dim
iferas3, **p .01, *p .05, and two-way analysis of variance p .05 but t test
www.sobp.org/journal
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wgene expressionmediated by KCl depolarization through activa-
tion of PKA and PKC pathways, ensuring that other ligand-recep-
tor interactions, which induce only PKC or Wnt signaling path-
ways, are less likely to trigger inappropriate expression of the
BDNF gene.
In addition to presenting data supporting the role of BE5.2 as a
filter of signaling information, our observations suggested that in
hippocampal and cortical cultures, BE5.2(C) was a stronger silencer
of BP4 activity than BE5.2(T), as it reduced the ability of BP4 to
respond to neuron activation by KCl depolarization. This observa-
tion is consistent with a possible role of the C allele in further
reducing BP4 response to neuron activation by KCl depolarization
with probable consequences for BDNF mRNA and protein levels in
these cell types. Consistent with this observation, a postmortem
study on brain tissues derived from human MDD and BD patients
who were homozygous or heterozygous for the C allele of
rs12273363 had significantly reduced hippocampal BDNF levels
compared with those who were homozygous for the major allele
(72). Indeed, decreased BDNF levels in the hippocampus and pre-
frontal cortex of MDD and BD patients are well described in post-
mortem studies (6,8,73). Taken together, our present study, when
examined in the light of these previous observations (72), is consis-
tent with the hypothesis that the C allele reduces BDNF expression
level by reducing BP4 activity to neuron activation, thus contribut-
ing to susceptibility to mood disorders.
In contrast tohippocampal andcortical cultures, theminor allele
of rs12273363 reduced the suppression effect of BE5.2 in amygdala
cultures, increasingBP4 response toneuron activationbyKCl depo-
larization. These observations are consistent with reports of SNPs
with tissue-specific effects, suggesting that regulatory SNPs can
affect promoter activity in a context-dependent manner (74,75).
Any increase in BP4 activity could hypothetically increase BDNF
expression in the amygdala, thus increasing neuroplastic processes
including dendritic and axonic arborization (76,77), neurogenesis
(1,78) and GABAergic neuron development (79,80). Although neu-
rogenesis is commonly known to occur in the dentate gyrus of the
hippocampus (81,82) and the subventricular zone (83), studieshave
also suggested that it might also occur in the amygdala (84,85).
Since the amygdala is involved in aversive fear response and emo-
tionalmemory, increase in these cellular processes in the amygdala
may contribute to anxiety behavior and poorer emotional memory
as observed in depressive disorder patients with enlarged
amygdala (86,87). Placing our data in the light of these previous
studies, it is possible that increased BDNF promoter IV activity by
the minor C allele of rs12273363 in the amygdala might increase
these cellular processes with consequences for anxiety behavior
and emotional memory.
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